Evidence map›Paper›PMID 41710892›Full record

ReviewFrontiers in immunology2026

Regulating the crosstalk between

Liting Peng, Zhiming Zhang, Yuan Hu, Huijia Chen, Yingru Tian, Hongyan Ling

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liting Peng *Department of Physiology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhiming Zhang *Department of Anesthesiology, The First People's Hospital of Chenzhou, The Chenzhou Affiliated Hospital, Hengyang Medical School, University of South China, Chenzhou, Hunan, China.
Yuan Hu *Department of Physiology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Huijia ChenDepartment of Physiology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yingru TianDepartment of Clinical College, Qujing University of Medicine & Health Sciences, Qujing, Yunnan, China.
Hongyan LingDepartment of Physiology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a common dementia in the elderly population, typically manifested through symptoms of cognitive impairment (CI) and memory loss. Pathologically, it is characterized by abnormally elevated levels of amyloid-β (Aβ) deposition and tau phosphorylation. Given the rapid rate of population aging, many scientists are investigating AD, focusing on its pathogenic mechanisms and potential treatments. Unfortunately, to date, no highly effective therapeutic strategies have emerged. Intriguingly, multiple studies have revealed alterations in the gut microbiome of individuals with AD, suggesting it may serve as a novel avenue for investigating AD pathogenesis.

Indexed as

Alzheimer DiseaseBifidobacteriumBrainGastrointestinal MicrobiomeProbioticsAmyloid beta-PeptidesAnimalsHumansAmyloid beta-PeptidesAlzheimer’s diseaseBifidobacteriumbrain-derived neurotrophic factorneuroinflammationneurotransmittershort-chain fatty acid

Identifiers

PMID41710892
PMCPMC12909532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.